• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Jeito Capital (Group)

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. *

 

	Start	2018-06-25 established
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017)
	Person 2	Clancy, Annette (Enyo Pharma 201806 Chair of Board of Directors)
	Region	Paris
	Country	France
	Street	33 rue La Fayette
	City	75009 Paris
		Address record changed: 2021-07-10
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	534,000,000 (capital under management (2021) 2021-11-29)
		* Document for �About Section�: Quell Therapeutics Ltd.. (11/29/21). "Press Release: Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform". London & Boston,
		Record changed: 2021-11-29

Advertisement

More documents for Jeito Capital (Group)

• [1] CDR-Life AG. (4/13/22). "Press Release: CDR-Life Announces $76 Million Raised in Series A Funding". Zürich....
• [2] Jeito Capital. (2/22/22). "Press Release: Jeito Capital Co-leads $65 Million Series A Financing in EyeBio". Paris....
• [3] Jeito Capital. (2/17/22). "Press Release: Jeito Capital Announces the Appointments of Dr Andreas Wallnöfer as Partner Investor and Isabelle Meyrier as Head of Legal". Paris....
• [4] NMD Pharma A/S. (2/15/22). "Press Release: NMD Pharma Raises €35 Million in a New Financing". Aarhus....
• [5] Quell Therapeutics Ltd.. (11/29/21). "Press Release: Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform". London & Boston,...
• [6] Jeito Capital. (9/20/21). "Press Release: Jeito Capital Becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)". Paris....
• [7] Jeito Capital. (7/28/21). "Press Release: Jeito Capital’s Dr. Rafaèle Tordjman Appointed to Promote the French Biotech Ecosystem". Paris....
• [8] Jeito Capital. (6/15/21). "Press Release: Jeito Capital Becomes Key Investor in Alentis Therapeutics as Part of $67 Million Series B Financing Round". Paris....
• [9] Pulmocide Ltd.. (5/27/21). "Press Release: Pulmocide Raises $92 Million in a Series C Financing to Fund Registration Program for PC945". London....
• [10] Jeito Capital. (5/27/21). "Press Release: Jeito Capital Leads Oversubscribed $92 million Series C Financing Round in Pulmocide". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.